Citations

Showing 10 of 108119 citations.

Teaching Ophthalmology Residents Clinical Optics Via a Flipped Classroom Curriculum
Tu, Daniel C., Park, Dong-Wouk , Krisciunas, Tammie C, Hwang, Thomas S.

Mayo Clinic

Journal of Academic Ophthalmology | March 27, 2019 | Volume: 11 | Issue: 01 | Pages: e16-e21

10.1055/s-0039-1683369 Get It

Background Clinical optics is an essential part of ophthalmology resident education that can be challenging for both learners and teachers when taught using a lecture format. The effectiveness of a flipped classroom approach in this context has not been formally evaluated. Objective The main purpose of this article is to compare the effectiveness of flipped classroom versus lecture-based clinical optics curricula in a graduate medical education setting. Design Retrospective, nonrandomized, pre- and post-interventional study from 2009 to 2016. Setting, Participants Ophthalmology residency program at the Casey Eye Institute, Oregon Health & Science University, an academic medical center in the United States. Participants included all ophthalmology residents able to take at least one Ophthalmic Knowledge Assessment Program (OKAP) examination during the years 2009 to 2016. Methods The clinical optics curriculum was changed from a lecture-based series to a flipped classroom curriculum and moved from the fall to winter during the 2012 to 2013 academic year. No major changes were made to the curriculum in other subject areas during the study period. Resident performance on the OKAP annual national in-service examination for the 4 years before and after the optics curriculum change was compared. Specifically, the scaled subtest scores from the Optics, Refraction, and Contact Lens subsection were examined, while scores from the 10 nonoptics subsections served as controls. Results Scores from 57 resident test administrations before the optics curriculum change and 59 after the optic curriculum change were available for comparison. The Optics, Refraction, and Contact Lens subsection mean scores were 50.37 ± 2.31 and 57.27 ± 2.47 before and after the optics curriculum change, respectively (mean ± 95% confidence interval). This was the only subsection score to show a statistically significant difference after the optics curriculum change (p = 0.00008). Conclusions and Relevance In comparison to a lecture-based curriculum, a flipped classroom approach to clinical optics education was found to be associated with higher ophthalmology resident performance on the optics subsection of the OKAP examination. Our study suggests that a flipped classroom format may be more effective than traditional lectures for teaching clinical optics in a graduate medical education setting.
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
Trippa, Lorenzo , Gaffey, Sarah, Arrillaga‐Romany, Isabel , Lee, Eudocia Q. , Rinne, Mikael L. , Ahluwalia, Manmeet S. , Colman, Howard , Fell, Geoffrey, Lassman, Andrew B. , Meredith, David M. , Schiff, David , Welch, Mary , Wen, Patrick Y. , Galanis, Evanthia , Ahluwalia, Manmeet S , Alexander, Brian M. , Arrillaga‐Romany, Isabel , Colman, Howard , Fell, Geoffrey G. , Groot, John de , Drappatz, Jan , Nabors, Burt , Santagata, Sandro , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

JCO Precision Oncology | March 27, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-13

10.1200/po.18.00071 | PMID 32914038 Get It

PURPOSE Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a novel adaptive platform trial (APT) to develop precision medicine approaches in GBM. METHODS INSIGhT compares experimental arms with a common control of standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide. The primary end point is overall survival. Patients with newly diagnosed unmethylated GBM who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. At the initiation of INSIGhT, three experimental arms (neratinib, abemaciclib, and CC-115), each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms may drop because of low probability of treatment impact on overall survival, and new arms may be added. Detailed information on the statistical model and randomization algorithm is provided to stimulate discussion on trial design choices more generally and provide an example for other investigators developing APTs. CONCLUSION INSIGhT (NCT02977780) is an ongoing novel biomarker-based, Bayesian APT for patients with newly diagnosed unmethylated GBM. Our goal is to dramatically shorten trial execution timelines while increasing scientific power of results and biomarker discovery using adaptive randomization. We anticipate that trial execution efficiency will also be improved by using the APT format, which allows for the collaborative addition of new experimental arms while retaining the overall trial structure.
The Future of Critical Care Lies in Quality Improvement and Education
Niven, Alexander S. , Herasevich, Svetlana , Pickering, Brian W. , Gajic, Ognjen , Niven, Alexander S , Gajic, Ognjen

Mayo Clinic

Annals of the American Thoracic Society | March 27, 2019 | Volume: 16 | Issue: 6 | Pages: 649-656

10.1513/annalsats.201812-847ip | PMID 30917286 Get It

Pipeline Endovascular Device vs Stent-Assisted Coiling in Small Unruptured Aneurysms: A Cost-Effectiveness Analysis
Malhotra, Ajay , Brinjikji, Waleed , Miller, Timothy , Malhotra, Ajay , Wu, Xiao Juan , Matouk, Charles , Sanelli, Pina C. , Gandhi, Dheeraj

Mayo Clinic

Neurosurgery | March 27, 2019 | Volume: 85 | Issue: 6 | Pages: E1010-E1019

10.1093/neuros/nyz130 | PMID 31329957 Get It

Abstract BACKGROUND Both stent-assisted coiling (SAC) and flow diversion with the Pipeline Embolization device (PED; Medtronic Inc) have been shown to be safe and clinically effective for treatment of small (<10 mm) unruptured aneurysms. However, the economic impact of these different techniques has not been established. OBJECTIVE To analyze the cost-effectiveness between stent-assisted coiling and flow diversion using PED, including procedural costs, long-term outcomes, and aneurysm recurrence. METHODS A decision-analytical study was performed with Markov modeling methods to simulate patients undergoing SAC or PED for treatment for unruptured aneurysms of sizes 5 and 7 mm. Input probabilities were derived from prior literature, and 1-way, 2-way, and probabilistic sensitivity analyses (PSA) were performed. RESULTS In base case calculation and PSA, PED was the dominant strategy for both the size groups, with and without consideration of indirect costs. One-way sensitivity analyses show that the conclusion remained robust when varying the retreatment rate of SAC from 0% to 50%, and only changes when the retreatment rate of PED > 49%. PED remained the more cost-effective strategy when the morbidity and mortality of PED increased by <55% and when those of SAC decreased by <37%. SAC only became cost-effective when the total cost of PED is >$73000 more expensive than the total cost of SAC. CONCLUSION With increasing use of PED for treatment of small unruptured anterior circulation aneurysms, our study indicates that PED is cost-effective relative to stent coiling irrespective of aneurysm size. This is due to lower aneurysm recurrence rate, as well as better health outcomes.
Rate and impact of venous thromboembolism in patients with ST-segment elevation myocardial infarction: Analysis of the Nationwide Inpatient Sample database 2003–2013
Al‐Ogaili, Ahmed , Ayoub, Ali , Quintero, Luis Diaz , Torres, Christian , Fuentes, Harry E , Fugar, Setri , Kolkailah, Ahmed A. , Dakkak, Wael, Tafur, Alfonso , Yadav, Neha , Quintero, Luis D , Fuentes, Harry E

Mayo Clinic

Vascular Medicine | March 27, 2019 | Volume: 24 | Issue: 4 | Pages: 341-348

10.1177/1358863x19833451 | PMID 30915913 Get It

Venous thromboembolism (VTE) and coronary artery disease are major health issues that cause substantial morbidity and mortality. New data have emerged suggesting that these two conditions could have a close relationship. Thus, we sought to determine the trends in annual rate of VTE occurrence in patients with ST-segment elevation myocardial infarction (STEMI) and measure its impact on in-hospital mortality, bleeding complications, and cost and length of hospitalization. We queried the 2003–2013 Nationwide Inpatient Sample databases to identify adults with primary diagnosis of STEMI. VTE events were then allocated. Inpatient outcomes of patients with VTE were compared to those without VTE. Out of 2,495,757 hospitalizations for STEMI, VTE was diagnosed in 25,149 (1%) hospitalizations. Patients who experienced VTE were older (mean age: 67.5 vs 64.8, p < 0.01) and had a higher proportion of black patients (10.1% vs 7.7%, p < 0.001) and females (40.1% vs 35%, p < 0.001) compared to patients without VTE. There was an increasing trend in the rate of VTE during the study period (2003: 0.8% vs 2013: 1.0%, p < 0.001). Patients with VTE had a prolonged hospitalization (median: 9 vs 3 days, p < 0.001), increased cost, higher risk of gastrointestinal bleeding (OR: 2.13, p < 0.001), intracranial hemorrhage (OR: 2.14, p < 0.001), blood transfusions (OR: 1.94, p < 0.001), and mortality (OR: 1.39, p < 0.001). The rate of VTE occurrence in patients with STEMI in our study was 10 per 1000 admissions. VTE was associated with more bleeding complications, longer hospital stays, higher costs, and mortality. These findings suggest that a more aggressive approach for VTE prophylaxis may be warranted in this population.
Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry
Bradley, Corey , Wang, Tracy Y., Li, Shuang , Robinson, Jennifer G. , Roger, Véronique L. , Goldberg, Anne C. , Louie, Michael J. , Lee, L. Veronica, Virani, Salim S. , Peterson, Eric D. , Návar, Ann Marie

Mayo Clinic

Journal of the American Heart Association | March 27, 2019 | Volume: 8 | Issue: 7 | Pages: No page available

10.1161/jaha.118.011765 | PMID 30913959 Get It

Background Many adults eligible for statin therapy for cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons for statin underutilization, including noninitiation, refusal, and discontinuation. Methods and Results This study included the 5693 adults recommended for statin therapy in the PALM (Patient and Provider Assessment of Lipid Management) registry. Patient surveys evaluated statin experience, reasons for declining or discontinuing statins, and beliefs about statins and cardiovascular disease risk. Overall, 1511 of 5693 adults (26.5%) were not on treatment. Of those not on a statin, 894 (59.2%) reported never being offered a statin, 153 (10.1%) declined a statin, and 464 (30.7%) had discontinued therapy. Women (relative risk: 1.22), black adults (relative risk: 1.48), and those without insurance (relative risk: 1.38) were most likely to report never being offered a statin. Fear of side effects and perceived side effects were the most common reasons cited for declining or discontinuing a statin. Compared with statin users, those who declined or discontinued statins were less likely to believe statins are safe (70.4% of current users vs. 36.9% of those who declined and 37.4% of those who discontinued) or effective (86.3%, 67.4%, and 69.1%, respectively). Willingness to take a statin was high; 67.7% of those never offered and 59.7% of patients who discontinued a statin would consider initiating or retrying a statin. Conclusions More than half of patients eligible for statin therapy but not on treatment reported never being offered one by their doctor. Concern about side effects was the leading reason for statin refusal or discontinuation. Many patients were willing to reconsider statin therapy if offered.
Transthyretin amyloidosis in Western Europe: a snapshot from the THAOS registry and a call for further perspectives
AbouEzzeddine, Omar F. , Ammirati, Enrico , AbouEzzeddine, Omar F

Mayo Clinic

European Heart Journal | March 27, 2019 | Volume: 43 | Issue: 5 | Pages: 401-404

10.1093/eurheartj/ehz205 | PMID 31006018 Get It

Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial
Ziegelmann, Matthew , Savage, Josh, Toussi, Amir , Alom, Manaf, Yang, David Y. , Köhler, Tobias , Trost, Landon , Yang, David, Yang Md, David

Mayo Clinic

Journal of Urology | March 27, 2019 | Volume: 202 | Issue: 3 | Pages: 599-610

10.1097/ju.0000000000000245 | PMID 30916626 Get It

Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease
Loftus, Edward V. , McKenna, Nicholas P. , Raffals, Laura E. , Loftus, Edward V , McKenna, Nicholas P , Lightner, Amy L.

Mayo Clinic

Current Drug Targets | March 27, 2019 | Volume: 20 | Issue: 13 | Pages: 1317-1322

10.2174/1389450120666190325130142 | PMID 30914021 Get It

Background: : The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. Objective: : To determine the risk of vedolizumab on postoperative complications. Method:: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn’s disease or ulcerative colitis individually, and those which included pediatric patients alone. Results:: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn’s disease literature. Conclusion:: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn’s disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.
Targeting FER Kinase Inhibits Melanoma Growth and Metastasis
Ivanova, Iordanka A. , Arulanantham, Shinthujah, Barr, Kevin , Cepeda, Mario , Parkins, Katie M. , Hamilton, Amanda M. , Johnston, Danielle , Peñuela, Silvia , Hess, David A. , Ronald, John A. , Dagnino, Lina

Mayo Clinic

Cancers | March 27, 2019 | Volume: 11 | Issue: 3 | Pages: 419

10.3390/cancers11030419 | PMID 30909648 Get It

Melanoma is one of the most aggressive types of tumors and exhibits high metastatic potential. Fes-related (FER) kinase is a non-receptor tyrosine kinase that has been implicated in growth and metastasis of various epithelial tumors. In this study, we have examined the role that FER kinase plays in melanoma at the molecular level. FER-depleted melanoma cells exhibit impaired Wnt/β-catenin pathway activity, as well as multiple proteomic changes, which include decreased abundance of L1-cell adhesion molecule (L1-CAM). Consistent with the pro-metastatic functions of these pathways, we demonstrate that depletion of FER kinase decreases melanoma growth and formation of distant metastases in a xenograft model. These findings indicate that FER is an important positive regulator of melanoma metastasis and a potential target for innovative therapies.